Skip to main content

Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications



The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors), before, during and after dental treatment in light of the more recent knowledges.


In dentistry and oral surgery, the major concerns in treatment of patients taking direct thrombin inhibitors and factor Xa inhibitors is the risk of haemorrhage and the absence of a specific reversal agent. The degree of renal function, the complexity of the surgical procedure and the patient’s risk of bleeding due to other concomitant causes, are the most important factors to consider during surgical dental treatment of patients taking NOAs. For patients requiring simple dental extraction or minor oral surgery procedures, interruption of NOA is not generally necessary, while an higher control of bleeding and discontinuation of the drug (at least 24 h) should be requested before invasive surgical procedures, depending on renal functionality.


The clinician has to consider that the number of patients taking NOAs is rapidly increasing. Since available data are not sufficient to establish an evidence-based dental management, the dentist must use caution and attention when treating patients taking dabigatran, rivaroxaban and apixaban.

Peer Review reports


In the last few years, new orally administered anticoagulants drugs (NOA) have been introduced in clinical practice for patients affected by various diseases and medical conditions that require use of extended-duration anticoagulant therapy (prophylaxis and treatment of pulmonary embolism and venous thrombosis, including prophylaxis after orthopaedic surgery; prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or prosthetic valves replacement; reduction of the risk of death, reinfarction and thromboembolic events after myocardial infarction) [1]. Similarly to subcutaneous or intravenously administered low-molecular-weight heparin (LMWH) and in contrast to coumarin derivatives (warfarin and acenocoumarol), these new medications interfere with very specific steps of the coagulation cascade. Three types of NOAs have recently been approved for use in the USA and in several European countries, including Italy. These are dabigatran etexilate, which acts as a direct thrombin inhibitor (DTI), rivaroxaban and apixaban that work as factor Xa inhibitors (FXaI). A fourth one FXaI, edoxaban, obtained the recent approval of the European Medicines Agency in Europe (April 2015, 23th) [2].

Advantages of dabigatran, rivaroxaban, apixaban and edoxaban have to be researched in their capacity to provide a stable anticoagulation at a fixed dose without the necessity to monitor the coagulation with routine laboratory exams (INR). They have a relatively rapid onset and reach peak concentration in few hours [3]. Furthermore, unlike vitamin K antagonists, they show a wide therapeutic margin, low drug- to- drug interactions and no significant food interactions [1, 4].

The progressive diffusion of NOAs has a direct repercussion on different dentistry specialties particularly in a surgical context. Because of their relatively recent introduction, specific studies regarding dental treatment of patients taking NOAs are available in literature only from 2012. No data exist regarding dental management of patients treated with edoxaban. The aim of this paper is to contribute to the discussion on how to approach patients taking dabigatran, rivaroxaban or apixaban, before, during and after dental treatment in light of the more recent knowledges. For this purpose, a comprehensive search of the literature carried out through PubMed ( Pubmed Central (, Medline ( and Cochrane databases (, was performed from inceptions to the last access in August 2015. “Dabigatran”, “Rivaroxaban”, “Apixaban”, “Anticoagulants”, “Dental”, “Oral”, “Surgery”, combined with the Boolean operator ‘AND’ were used as search algorithm. Studies that provided general and specific information on NOAs in a dental context have been identified and selected.


Dabigatran etexilate (Pradaxa®)

Dabigatran etexilate is a specific, reversible DTI that, after oral administration, is rapidly absorbed and converted in its active form, dabigatran, through esterase-catalyzed hydrolysis in plasma. Mechanism of action of dabigatran is to bind with the active site on free and clot-bound thrombin (factor IIa) so it cannot transform fibrinogen into fibrin [5]. It has a rapid onset of action with a peak plasma concentration at 0.5–4 h. The half –life elimination is 12–14 h in healthy patients, 14–17 h in elderly and up to 27 h in patient with severe renal dysfunction (creatinine clearance <15–30 ml/min) [6]. Dabigatran is not a substrate of the hepatic cytochrome P-450. The efficacy of dabigatran has been firstly assessed by the RE-LY trial in 2009 [7]. Results showed that, on a total of 18113 patients affected by atrial fibrillation recruited for the study, a dabigatran dose of 150 mg twice daily was associated to lower rates of stroke and systemic embolism but similar rates of major bleeding when compared with warfarin assumption. At a 110 mg twice daily, dabigatran showed similar rates of stroke and systemic embolism when compare with warfarin but with significantly lower cases of major bleeding. The most important finding was that the rate of hemorrhagic stroke with both doses of dabigatran was less than one-third that of warfarin, without any reduction in the efficacy against ischemic stroke [7].

Although the prescription cost of dabigatran is significantly higher than that of warfarin, the overall cost to the health care system seems to be more cost-effective than warfarin [8].

Monitoring of dabigatran is generally unnecessary; however, in case of emergency, the thrombin clotting time (TT) and the ecarin clotting time (ECT) are the most sensitive tests for quantifying anticoagulation rate. The activated partial thromboplastin time (aPTT) is less sensitive, especially for higher doses of dabigatran but anyway recommended in case of emergency situation owing to its broad availability [9, 10]. The INR test is insensitive to the activity of this drug and might not be elevated in patients taking dabigatran [11].

For patients who experience minor bleeding events, the delaying of the next dose or the discontinuation should be indicated although this choice has to be evaluated with prudence considering the possible risk of ischemic events [12]. For moderate or severe bleeding, treatments include mechanical compression, surgical intervention, fluid replacement, hemodynamic support, oral charcoal application (for recent ingestion of dabigatran) and haemodialysis. For life-threatening bleeding, treatment includes administration of prothrombin complex concentrates or charcoal and supportive measures [13] although recent investigations showed no effect of prothrombin complex concentrates on aPTT, TT and ECT [12]. In October, 2015, the U.S. Food and Drug Administration approved idarucizumab, a monoclonal antibody fragment (Praxbind®, Boehringer Ingelheim Pharmaceuticals, Inc., Germany) for the treatment of patients taking dabigatran etexilate when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding [14]. Idarucizumab rapidly and completely reversed (within minutes) the anticoagulant activity of dabigatran in 88 to 98 % of patients in an initial clinical study [15]. The approval of idarucizumab will substantially influence the approach to haemorrhagic complications related to dabigatran probably solving the concerns that had been raised for the lack of a proven reversal strategy with respect to severe bleeding events in patients taking this NOA [12, 16].

Discontinuing anticoagulants, including dabigatran, for elective surgery or invasive procedures places patients at an increased risk of stroke and, if discontinuation is necessary, dabigatran should be restarted as soon as possible [17].

Perioperative bleeding associated to dabigatran etexilate

In the RE-LY trial (dabigatran versus warfarin in the treatment of atrial fibrillation), the rate of major bleeding associated with an invasive procedure or surgery was expressed as percentage [18]. Major bleeding was similar with dabigatran 110 mg twice daily (3.8 %), dabigatran 150 mg twice daily (5.1 %), and warfarin (4.6 %). Bleeding was greater in those undergoing urgent surgery (18 %, 18 %, and 22 %, respectively). The risk of major bleeding was increased in those who received bridging anticoagulation compared with those who did not, an effect that was seen both with dabigatran (major bleeding with and without bridging, 6.5 % versus 1.8 %) and warfarin (6.8 % versus 1.6 %) [19].

Perioperative thromboembolic risk associated to dabigatran etexilate

Of the 4591 patients who underwent elective procedures or surgery in the RE-LY trial, the perioperative thromboembolic risk was 1.2 %, based on a composite endpoint of stroke, cardiovascular death, and pulmonary embolism. There were no differences in thromboembolic risk with dabigatran versus warfarin, or with the high versus the low dabigatran dose. However, urgent surgery was associated with a higher risk of ischemic stroke or systemic embolism than elective surgery (warfarin: 1.8 % versus 0.4 %; dabigatran 150 mg twice daily: 1.4 % versus 0.4 %; dabigatran 110 mg twice daily: 2.8 % versus 0.3 %) [18].

Dental consideration for patients taking dabigatran

The major concern in treatment of patients taking DTIs is the risk of haemorrhage in dentistry and oral surgery too. The recent approval of idarucizumab will help in solving the concerns related to the absence of a specific reversal agent for dabigatran. To date, there have been no published studies on the incidence of bleeding events among patients receiving dabigatran. However, several studies demonstrated that the risk of haemorrhage for patients taking DTIs is similar to those taking warfarin when the INR value ranges between 2 and 3 (except for gastrointestinal bleeding) [7, 18, 20]. For patients requiring simple dental extraction or minor oral surgery procedures (as localized surgical extraction, localized periodontal surgery, apicectomies, incisional biopsies or excision of localized mucosal lesion), it can be assumed that the risk is similar to that of patients taking vitamin k antagonists and with an INR < 3 [12]. One of the first rules to reduce the risk of bleeding, is to perform the surgical procedures as late as possible after the most recent assumption of dabigatran. After surgery, local haemostatic measures such as suturing, gelatine sponge or cellulose mesh, tranexamic acid mouth rinse (twice daily for 2–5 days) may help in controlling postoperative bleeding [21, 22]. Elective invasive surgical procedures as multiple surgical extractions, removal of extensive intraosseous lesions or maxillofacial surgery, should request an higher control of bleeding and even the decision of discontinuation of the drug because some dental patients may have a higher risk of bleeding when taking dabigatran [6]. A patient with high bleeding risk in a surgical context is a subject that could develop hemorrhagic complications (also life-threatening) that need important haemostatic interventions (like tissue or vascular sutures, use of pro-coagulants or reversal agents). Several factors concur in the assessment of bleeding risk and these are patient-dependent or surgery-dependent. Patient-dependent factors are age, renal functionality, congenital or acquired alterations of the coagulation, assumption of antiplatelet or anticoagulant drugs (i.e. patients older than 75 years and taking acetylsalicylic acid, long term NSAIDs or clopidogrel or prasugrel) [23]. Surgery-dependent factors are correlated to the invasiveness and difficulty of the surgery. To assess the risk of bleeding, patient-dependent factors and surgery-dependent factors must be considered together. In this sense an accurate anamnesis and surgical planning are extremely important to intercept these high- risk categories. Actually, the best available protocol regarding discontinuation of dabigatran in elective surgery is that proposed by van Ryn et al. [9]. It takes into account the degree of renal function, the complexity of the surgical procedure and the patient’s risk of bleeding due to other concomitant causes (Table 1). Additionally, TT or aPTT performed 6 to 12 h prior to surgical treatment can indicate, when normal, if the anticoagulant effect of dabigatran has resolved [6].

Table 1 Guide to discontinuation of dabigatran before elective surgery; indications are matched for renal function and risk of bleeding (van Ryn et al. 2010) [9]

Dabigatran should be restarted once a stable clot has formed, usually within 24–48 h following surgery, because of the rapid onset of this drug [1].

Anyway, all the modifications of the therapy with dabigatran have to be discussed with the patient’s physician in terms of risks-benefit to optimize the surgical treatment without increasing the risk of thromboembolism. In patients needing a maintenance of anticoagulation during extensive major oral surgery, a switch to LMWH should be considered [12]. Furthermore, in the postoperative phase, attention has to be paid to the administration of analgesics. Although dabigatran does not directly interact with NSAIDs, both increase the risk of bleeding [12]. For this reason, prescription of NSAIDs should be made with caution, preferring alternative drugs for pain management. Paracetamol or opioid medications are safer alternatives for patients taking dabigatran [12].

Dabigatran acts as a substrate of P- glycoprotein 1 (P-gp 1), an important protein of the cell membrane that pumps many foreign substances out of cells. Concomitant assumption of strong P-gp 1 inducers like rifampicin, dexamethasone and carbamazepine, has been reported to significantly decrease the plasma concentration-versus time curve and peak serum concentration of dabigatran. For this reason, these drugs are not recommended in patients taking DTIs [1]. A single dose of 400 mg of ketoconazole, a P-gp 1 inhibitor, was reported to increase the peak plasma concentration of dabigatran to 135 % while concomitant therapy with clarithromycin, a moderate P-gp 1 inhibitor, has substantially no effects on dabigatran concentrations. The administration of P-gp 1 inhibitors like ketoconazole (and possibly itraconazole, erythromycin, clarithromycin) should be avoided or, if necessary, a reduced dose of dabigatran may be indicated [1].

Rivaroxaban (Xarelto®)

Rivaroxaban is an orally administered selective, reversible direct FXaI that binds with the part of factor XaI that catalyzes the activation of prothrombin (factor II) [1]. Rivaroxaban can inhibit free factor Xa but also clot-bound factor Xa and factor Xa bound to the prothrombinase complex [5]. The drug shows a rapid onset and reaches the peak plasma concentration in 2.5–4 h after oral administration (once daily). The half-life is 5.7–9.2 h (up to 12–13 h in patients older than 75 years) and approximately 51 % of rivaroxaban undergoes metabolic degradation without involving cytochrome P-450. FXaIs, including rivaroxaban, slightly prolong prothrombin time (PT) and aPTT. No routine monitoring of rivaroxaban is generally required however, in case of an emergency, anti factor Xa is reported as the most accurate measurement of anticoagulation.

Rivaroxaban is indicated in the prevention of venous thromboembolism in adults subjected to elective hip or knee replacement surgery, in the treatment of deep venous thrombosis (DVT) and pulmonary embolism following DVT in adults patients [4]. The efficacy of rivaroxaban in comparison with warfarin, was tested in the ROCKET-AF study, a large clinical trial that assessed the effectiveness of the drugs in reduction of ischemic stroke or systemic embolism in patient affected by atrial fibrillation [24]. Recent meta-analysis and systematic reviews showed that FXaI significantly reduces the number of strokes and systemic embolic events compared with warfarin in patients with atrial fibrillation. FXaI also seems to reduce the number of major bleedings and intracranial haemorrhages compared with warfarin [25, 26].

Rivaroxaban has not a specific antidote [1] although some studies suggest the use of recombinant factor VIIa or active concentrate prothrombin complex to antagonizing the anticoagulant effect [27]. Recently, a modified form of factor Xa is being studied as a potential antidote for factor Xa inhibitors. This recombinant protein (r-Antidote, PRT064445, Portola Pharmaceuticals) is currently undergoing clinical trials for effectiveness of reversal of the effects of oral factor Xa inhibitors (rivaroxaban and apixaban) [28].

Perioperative bleeding associated to rivaroxaban

Minor bleeding events have been observed in 4–7 % of patients, while < 1–2 % experienced major bleeding events [29].

In the ROCKET AF trial (rivaroxaban versus warfarin for atrial fibrillation), the rate of major bleeding associated with an invasive procedure or surgery was 2.3 % [30]. Bleeding was similar between the two anticoagulants, and between patients who received bridging anticoagulation and those who did not.

Perioperative thromboembolic risk associated to rivaroxaban

In the ROCKET AF trial, a randomized, double-blind, double-dummy study of rivaroxaban and warfarin in non-valvular atrial fibrillation, baseline characteristics, management, and outcomes, including stroke, non-central nervous system systemic embolism, death, myocardial infarction, and bleeding, were reported in participants who experienced temporary interruption (TI, 3–30 days) for any reason [30]. The at-risk period for outcomes associated with TI was from TI start to 30 days after resumption of study drug. In 14236 participants who received at least 1 dose of study drug, 4692 (33 %) experienced TI. Participants with TI were similar to the overall ROCKET AF population in regard to baseline clinical characteristics. Only 6 % (n = 483) of TI incidences involved bridging therapy. Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and warfarin-treated participants (0.30 % versus 0.41 % per 30 days).

Rivaroxaban is the only NAO, with a study that considered interruption of treatment, for apixaban and dabigatran further studies are needed.

Dental consideration for patients taking rivaroxaban

To date, there are no clinical trials supporting specific measures in the event of haemorrhage in dental patients taking rivaroxaban. The most current informations suggest that interruption of rivaroxaban is not required for simple surgery like dental extraction [1, 31]. In general, the indications given for dabigatran are also applicable to rivaroxaban. Therefore, the drug can be normally administered without discontinuation, for uncomplicated extractions and other similar dental procedures in patients with normal renal functionality [6]. As dabigatran, rivaroxaban should be discontinued at least 24 h before oral and maxillofacial surgery in patients at risk of excessive bleeding or impaired haemostasis [1]. Patients with severe renal impairment may necessitate a period > 24 h of discontinuation because they show a significant increase in maximum plasma concentration and longer half- life of rivaroxaban [1]. When discontinued, rivaroxaban should not be restarted immediately after surgery, but usually within 24–48 h due to its rapid onset [1]. As for dabigatran, the decision of discontinuation has to be carefully discussed with the patients’s physician to avoid possible thrombo-embolic complications.

PT and APTT are not clinically useful in assessing the anticoagulant effect before oral surgery in patients taking rivaroxaban [1, 17].

When prescribing medical therapy for the treatment of oral and dental pathologies, clinician has to remember that two third of rivaroxaban is metabolized by cytochrome P-450 system (in particular by cytochrome P3A4) and it is also a substrate of P-gp transporters [6]. Concomitant use of strong CYP3A4 and P-gp inhibitors such as ketoconazole, itraconazole, voriconazol and posaconazole can increase serum concentration of rivaroxaban and should be avoided. Eventually, only fluconazole can be coadministered with caution [6]. Clarithromycin, a strong CYP3A4 inhibitor and a moderate P-gp inhibitor, slightly increases peak serum concentration of rivaroxaban when administered with a dose of 500 mg twice daily. Also erythromycin (a moderate CYP3A4 and P-gp inducer) does not lead to a clinically significant increase of serum concentration of rivaroxaban when taken at a dose of 500 mg, times per day [1]. Conversely, rifampicin, a CYP3A4 inducer, may increase the metabolism of rivaroxaban decreasing the level of anticoagulation [6].

There are no reports of interaction between rivaroxaban and amoxicillin, cephalexin, cefazolin, ampicillin or clindamycin [17]. Therefore, none of these antibiotics can be used safely.

No clinically relevant interaction has been observed between rivaroxaban and NSAIDs, although a study by Kubitza et al. [32] showed a significant increase in bleeding time for patients taking rivaroxaban and naproxen in comparison of those taking rivaroxaban alone. However, the increased bleeding time resulted not clinically relevant. It has also been observed that patients co-medicated with opioid drugs experienced higher major or non-major clinically relevant post-surgical bleeding compared with those co-medicated with NSAIDs. Based on these informations, prudence is needed when using NSAIDs and opioid drugs in patients taking rivaroxaban. A careful monitoring of the entity of bleeding is indicated in these patients especially during and after surgical dental procedure [1].

Apixaban (Eliquis®)

Apixaban is the most recently introduced direct anticoagulant. It is a reversible orally administered FXaI with the same therapeutic indications of dabigatran and rivaroxaban. After intake, the peak plasma concentration is reached in about 1–3 h with an oral bioavailability of approximately 60 %. The half-life of the drug is about 12 h and it is excreted almost totally in bile [4]. As rivaroxaban, no specific reversal agent exists for apixaban. In case of emergency situations, recombinant factor VIIa, recombinant factor Xa or activated thrombin complexes can be used. In situations of normal bleeding, the delay or discontinuation of the next dose can be sufficient to resolve bleeding. However, few data are available for correct management of apixaban in case of haemorrhage and further studies are needed in this respect.

Perioperative Bleeding associated to apixaban

Data of ARISTOTLE trial (apixaban versus warfarin for atrial fibrillation) [33] showed that the rate of major bleeding associated with an invasive procedure or surgery was 1.8 %. Major bleeding was similar in those receiving apixaban or warfarin (1.6 % versus 1.9 %), and in those who continued or interrupted apixaban (1.6 % versus 1.7 %). In the warfarin arm, the rate of major bleeding was 3.0 % in those who continued warfarin versus 1.3 % in those who interrupted it. Many of the procedures were low risk (dental extraction, ophthalmologic surgery, colonoscopy or upper endoscopy).

Perioperative thromboembolic risk associated to apixaban

During 9260 procedures performed on patients in the ARISTOTLE trial, the perioperative thromboembolic risk was 0.57 % for warfarin and 0.35 % for apixaban [33].

Dental considerations for patients taking apixaban

Because apixaban is one of the most recently marketed direct anticoagulant (2013), few data or guidelines are available for management of dental patient taking this drug. In general, the same indications used for dabigratran and rivaroxaban can be valid. Actually, there is no necessity to suspend apixaban before dental surgery in patients with no comorbidities for increased bleeding but further studies are needed in this respect. Similarly to rivaroxaban, administration of potent CYP3A4 and P-gp inhibitors are contraindicated [4].

Final considerations

Summary of main characteristics of dabigratran etexilate, rivaroxaban and apixaban is shown in Table 2. Table 3 summarizes the more recent guidelines for dental management of patients taking NOAs.

Table 2 Principal characteristics of new oral anticoagulants (NOAs)
Table 3 Summary of the more recent guidelines for dental management of patients taking NOAs

The analysis of the literature showed that the interindividual pharmacokinetic variability of NOAs is large. The four drugs that are most advanced in their clinical development and regulatory proceedings (dabigatran etexilate, rivaroxaban, apixaban and edoxaban) differ in their rate and extent of digestive adsorption and in the mechanisms and rate of elimination, predominantly renal or hepatobiliary.

However, the absorption, distribution, metabolism and elimination of these drugs are governed by many variables: liver and/or renal function, sex, weight, age, genetic polymorphisms of enzyme or efflux systems, drug-drug interference, etc. It follows that for a given patient, the residual concentration at a given time after halting treatment cannot be accurately calculated from the average values of the pharmacokinetics in the target population.

Once the thromboembolic and bleeding risks have been estimated, a decision can be made about whether the anticoagulant should be interrupted or continued. Data comparing the relative benefits of continuing anticoagulation versus interrupting an anticoagulant are limited, and decisions that balance thromboembolic and bleeding risks must be made on a case-by-case basis. No scoring system can substitute for clinical judgment in this decision-making.

Dental procedures are generally considered to confer a low risk of bleeding, and anticoagulation can be continued in most patients during these procedures. The evidence of continuing anticoagulation during selected low bleeding risk surgery comes from patients receiving warfarin with an INR in the therapeutic range [34, 35]. Conversely, the anticoagulant should be discontinued if the surgical bleeding risk is considered high (i.e. multiple extractions >5, surgery lasting more than 45 min, head and neck cancer, extensive oral and maxillofacial surgery in patients with comorbidities) [4, 36]. If a concomitant very high or high thromboembolic risk exists, the period without anticoagulation should be limited to the shortest possible interval. Unlike patients taking vitamin K antagonist, bridging with LMWH could be not required for those with very high or high thromboembolic risk who are receiving a DTI or FXaIs, in light of the shorter half-lives of these agents and the recent introduction of DTI reversal agent [12, 14].

NOAs are seeing increased use in Europe and USA, thanks to their efficacy and benefits. However, few data are still available regarding dental management of patients taking dabigatran, rivaroxaban, apixaban and edoxaban. The lack of data with regards to bleeding risk in dental treatment is still a concern among clinicians. For this reason, clinical prospective studies are strongly encouraged to determine the perioperative risks after oral surgical procedures and to define evidence-based guidelines for dental management of patients taking NOAs.


Dabigatran etexilate, rivaroxaban, apixaban and edoxaban are four recently introduced drugs for the treatment of patients affected by various diseases and medical conditions that require use of extended-duration anticoagulant therapy. These new oral anticoagulant agents (NOAs) interfere with very specific steps of the coagulation cascade: dabigatran etexilate acts as a direct thrombin inhibitor (DTI), rivaroxaban, apixaban and edoxaban work as factor Xa inhibitors (FXaI). Since no specific reversal agents are available for these drugs (except for dabigatran etexilate), surgical dental treatment of patients taking NOAs requires particular attention in light of the bleeding risk associated to the procedure. Interruption of the NOA administration is generally not necessary for simple surgery as single dental extraction, while suspension has to be considered for extensive surgical treatments and/or in cases of patient’s comorbidities as renal impairment, advanced age or concomitant anti-platelet therapies.

Although the number of patients treated with NOAs is increasing, currently no established evidence-based guidelines are still available in literature for dental management of this cohort of patients. For this reason, further clinical prospective studies are needed to investigate the bleeding risk and haemostasis associated to surgical dental procedures.



novel oral anticoagulant(s)


low-molecular-weight heparin


direct thrombin inhibitor


factor Xa inhibitor


international normalized ratio


thrombin clotting time


ecarin clotting time


activated partial thromboplastin time


deep venous thrombosis


nonsteroidal antinflammatory drug

P-gp 1:

P- glycoprotein 1


prothrombin time


  1. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431–41.

    Article  PubMed  Google Scholar 

  2. European Medicines Agency/Committee for Medical Products for Human Use: Lixiana (edoxaban). Accessed 11 May 2015.

  3. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:e191–5.

    Article  PubMed  Google Scholar 

  4. Mingarro-de-León A, Chaveli-López B. Alternative to oral dicoumarin anticoagulants: Considerations in dental care. J Clin Exp Dent. 2013;5:e273–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010;113:726–45.

    PubMed  Google Scholar 

  6. O’Connell JE, Stassen LF. New oral anticoagulants and their implications for dental patients. J Ir Dent Assoc. 2014;60:137–43.

    PubMed  Google Scholar 

  7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.;RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

  8. Sorensen SV, Kansal AR, Connolly S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908–19.

    Article  PubMed  Google Scholar 

  9. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.

    Article  PubMed  Google Scholar 

  10. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol. 2010;85:185–7.

    Article  PubMed  Google Scholar 

  11. Thompson CA. First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR. Am J Health Syst Pharm. 2010;67:1974–6.

    Article  PubMed  Google Scholar 

  12. Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013;79:d74.

    PubMed  Google Scholar 

  13. Dubois EA, Cohen AF. Dabigatran etexilate. Br J Clin Pharmacol. 2010;70:14–5.

    Article  PubMed  PubMed Central  Google Scholar 

  14. U.S. Food and Drug Administration. Accessed 9 November 2015.

  15. Pollack Jr CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373:511–20.

    Article  PubMed  Google Scholar 

  16. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    Article  PubMed  Google Scholar 

  17. Wynn RL. New antiplatelet and anticoagulant drugs. Gen Dent. 2012;60:8–11.

    PubMed  Google Scholar 

  18. Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.

    Article  PubMed  Google Scholar 

  19. Douketis JD, Healey JS, Brueckmann M, Wallentin L, Oldgren J, Yang S, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113:625–32.

    Article  PubMed  Google Scholar 

  20. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  PubMed  Google Scholar 

  21. Borea G, Montebugnoli L, Capuzzi P, Magelli C. Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol. 1993;75:29–31.

    Article  PubMed  Google Scholar 

  22. Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case–control study. Thromb Haemost. 2010;104:972–5.

    Article  PubMed  Google Scholar 

  23. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285–6.

    Article  PubMed  Google Scholar 

  24. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340–7.

    Article  Google Scholar 

  25. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;8:CD008980.

    Google Scholar 

  26. Nunes JP, Rodrigues RP, Gonçalves FR. Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation. Open Heart. 2014;1:e000080.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Tsiara S, Pappas K, Boutsis D, Laffan M. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol. 2011;52:52–67.

    PubMed  Google Scholar 

  28. Das A, Liu D. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015;4:25.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol. 2010;3:227–41.

    Article  PubMed  Google Scholar 

  30. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129:1850–9.

  31. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876–86.

    Article  PubMed  Google Scholar 

  32. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59–7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol. 2007;63:469–76.

    Article  PubMed  Google Scholar 

  33. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124:3692–8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Blinder D, Manor Y, Martinowitz U, et al. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg. 2001;30:518–21.

    Article  PubMed  Google Scholar 

  35. Malden N. Dental procedures can be undertaken without alteration of oral anticoagulant regimen. Evid Based Dent. 2005;6:11.

    Article  PubMed  Google Scholar 

  36. Hong CH, Islam I. Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf. 2013;4:166. doi:10.4172/2155-9864.1000166.

    Google Scholar 

  37. Breik O, Tadros R, Devitt P. Thrombin inhibitors: surgical considerations and pharmacology. ANZ J Surg. 2013;83:215–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Fulvia Costantinides.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

FC and LP collected the dental literature; FC wrote the manuscript; RR, LP and MM revised it critically. All authors read and approved the final version of the manuscript.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costantinides, F., Rizzo, R., Pascazio, L. et al. Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral Health 16, 5 (2016).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: